Pacira Pharmaceuticals, Inc.

10450 Science Center Drive
San Diego, CA 92121
(858) 625 2424

5 Sylvan Way
Parsippany, NJ 07054
(973) 254 3560

TAKING CARE OF PATIENTS, TODAY AND TOMORROW

Company Overview

Corporate Profile
Pacira Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development, commercialization and manufacture of new pharmaceutical products, based on its proprietary DepoFoam® drug delivery technology, for use in hospitals and ambulatory surgery centers.
Stock Quote
PCRX (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$85.76
Change (%) Stock is Down 3.09 (3.48%)
Volume1,248,620
Data as of 04/01/15 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
DateTitle 
03/26/15Pacira Announces Data Reinforcing Benefits of EXPAREL® for Postsurgical Pain Control Following Total Hip and Knee Replacement Surgery
-- Results Presented at the 2015 Annual Meeting of the American Academy of Orthopedic Surgeons Find Overall Hospital Cost Savings of More Than $1.5 Million -- PARSIPPANY, N.J.--(BUSINESS WIRE)--Mar. 26, 2015-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced data demonstrating the benefits associated with the use of EXPAREL® (bupivacaine liposome injectable suspension) in a study of over 2,200 hip and knee replacement patient... 
Printer Friendly Version
03/23/15New Data Demonstrate Reduced Opioid Requirements Following Use of EXPAREL in Hysterectomy and Mastectomy Procedures
Data Presented at the 2015 Annual Meeting of the International Anesthesia Research Society PARSIPPANY, N.J.--(BUSINESS WIRE)--Mar. 23, 2015-- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced results of two data presentations on the impact of EXPAREL® (bupivacaine liposome injectable suspension) on postsurgical opioid requirements in patients undergoing hysterectomy or mastectomy. The data were presented during two poster sessi... 
Printer Friendly Version
03/04/15Pacira Pharmaceuticals, Inc. to Present at the Barclays Global Healthcare Conference
PARSIPPANY, N.J.--(BUSINESS WIRE)--Mar. 4, 2015-- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced Dave Stack, president, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present at the Barclays Global Healthcare Conference at 3:50 p.m. ET on Wednesday, March 11, in Miami. Mr. Stack is expected to present an overview of the company. A live audio webcast of the Pacira presentation can be accessed by ... 
Printer Friendly Version
03/02/15Pacira Receives Complete Response Letter from FDA for sNDA Seeking Approval of EXPAREL® Use in Nerve Block to Provide Postsurgical Analgesia
PARSIPPANY, N.J.--(BUSINESS WIRE)--Mar. 2, 2015-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced the receipt of a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) following a review of its supplemental New Drug Application (sNDA) for the use of EXPAREL® (bupivacaine liposome injectable suspension) in nerve block to provide postsurgical analgesia. Pacira will immediately schedule an End-of-Review meeting ... 
Printer Friendly Version

Corporate Presentation

DateTitle
03/16/15
Coporate Presentation
01/22/15
Analyst Day Presentation
Upcoming EventsMore >>
There are currently no events scheduled.
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Pacira Pharmaceuticals, Inc. posts new information to the site. Just enter your e-mail address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
Contact Investor Relations:
Jessica Cho
(973) 254-3574
Jessica.Cho@pacira.com